Skip to content
Clinical Trials – home

Rare diseases

Investigational molecules

Locations

Our offerNewsroom

SpainBack to Spain

Clinical trials in Bilbao – page 9

175 clinical trials in Bilbao, Spain across 2 research sites. Every trial is listed in the EU Clinical Trials Register and updated daily.

SpainOur site in SpainEnsayosClinicos.es(opens in a new tab)
Bilbao at a glance
175
clinical trials
  • Paediatric trials0
  • Research sites2
Type of trial
Recruitment status
Quick filters

175 trials in Bilbao

Open in trial search

Triple negative breast cancer

Not recruiting

Study of datopotamab deruxtecan with or without durvalumab compared to standard treatment for patients with Stage I-III triple-negative breast cancer who have remaining cancer after initial therapy

Registered drugNo placebo
Countries:SpainSpain
  • Participants:18–64 years · 65+ years
  • Substances:Capecitabine
  • Sponsor:AstraZeneca AB

Rheumatoid arthritis

Not recruiting

Study of lutikizumab and ravagalimab in adults with moderate to severe rheumatoid arthritis

Investigational
Countries:SpainSpain
  • Participants:18–64 years · 65+ years
  • Substances:Lutikizumab
  • Sponsor:AbbVie Deutschland GmbH & Co. KG

Multifocal motor neuropathy

Not recruiting

Study comparing empasiprubart versus intravenous immunoglobulin for treating adults with multifocal motor neuropathy

Registered drug
Countries:SpainSpain
  • Participants:18–64 years · 65+ years
  • Substances:Empasiprubart
  • Sponsor:Argenx

Chronic myeloid leukaemia

Not recruiting

Study for Adults with Chronic Myeloid Leukemia Using Asciminib Alone or with Nilotinib

Registered drugNo placebo
Countries:SpainSpain
  • Participants:18–64 years · 65+ years
  • Substances:Nilotinib
  • Sponsor:Fondazione Gimema Franco Mandelli Onlus

Breast cancer+1

Not recruiting

Study of PF-07220060 and Letrozole for Adults with HR-Positive, HER2-Negative Advanced Breast Cancer Without Prior Treatment

Registered drugNo placebo
Countries:SpainSpain
  • Participants:18–64 years · 65+ years
  • Substances:Abemaciclib
  • Sponsor:Pfizer Inc.

Interstitial lung disease+1

Not recruiting

Study to Test if Nerandomilast (BI 1015550) Helps Patients with Interstitial Lung Disease Related to Rheumatic Diseases

Investigational
Countries:SpainSpain
  • Participants:18–64 years · 65+ years
  • Substances:1-[[(5R)-2-[4-(5-Chloro-2-Pyrimidinyl)-1-Piperidinyl]-6,7- Dihydro-5-Oxidothieno[3,2-D]Pyrimidin-4- Yl]Amino]-Cyclobutanemethanol
  • Sponsor:Boehringer Ingelheim Espana S.A.

Hormone receptor positive HER2 negative breast cancer

Not recruiting

Study Comparing Elacestrant and Standard Endocrine Therapy for Patients with Early Breast Cancer at High Risk of Recurrence

Registered drugNo placebo
Countries:SpainSpain
  • Participants:18–64 years · 65+ years
  • Substances:Anastrozole
  • Sponsor:Stemline Therapeutics Inc.

HIV infection

Not recruiting

Study on the Effectiveness of Cabotegravir and Rilpivirine for People with HIV-1 Who Have Not Responded Well to Oral Treatment

Registered drugNo placebo
Countries:SpainSpain
  • Participants:0–17 years · 18–64 years · 65+ years
  • Substances:Cabotegravir
  • Sponsor:Viiv Healthcare UK Limited

Cardiac amyloidosis

Not recruiting

Study to Evaluate the Safety and Effectiveness of Vutrisiran in Patients with Transthyretin Amyloidosis and Heart Disease

Registered drugNo placebo
Countries:SpainSpain
  • Participants:18–64 years · 65+ years
  • Substances:Vutrisiran
  • Sponsor:Alnylam Pharmaceuticals Inc.

Bladder cancer recurrent+1

Not recruiting

Study on Mycobacterium Bovis Bacillus Calmette-Guérin for High-risk Non-muscle Invasive Bladder Cancer Patients

InvestigationalNo placebo
Countries:SpainSpain
  • Participants:18–64 years · 65+ years
  • Sponsor:Biofabri S.L.

Paroxysmal nocturnal haemoglobinuria

Not recruiting

Long-term safety and effectiveness study of pozelimab and cemdisiran combination treatment in adults with paroxysmal nocturnal hemoglobinuria (PNH)

InvestigationalNo placebo
Countries:SpainSpain
  • Participants:18–64 years · 65+ years
  • Substances:Cemdisiran
  • Sponsor:Regeneron Pharmaceuticals Inc.

Paroxysmal nocturnal haemoglobinuria

Not recruiting

Study on the Safety and Effectiveness of Pozelimab and Cemdisiran for Adults with Paroxysmal Nocturnal Hemoglobinuria Not Recently Treated with Complement Inhibitors

Registered drugNo placebo
Countries:SpainSpain
  • Participants:18–64 years · 65+ years
  • Substances:Cemdisiran
  • Sponsor:Regeneron Pharmaceuticals Inc.

Other cities in Spain

The busiest research cities in the country

All 218 cities in Spain

Clinical research in Bilbao

What the registry says about research in the country

01 Oncology Research

Groundbreaking trials focusing on leukemia and various types of breast cancer treatments, including studies on advanced and metastatic cases. Research includes evaluation of novel combination therapies and targeted treatments.

  • BCR-ABL1+ Chronic Myeloid Leukemia
  • HER2-negative Breast Cancer
  • Non-muscle Invasive Bladder Cancer
  • Non-small Cell Lung Cancer

Multiple clinical trials are testing innovative therapeutic approaches and assessing treatment effectiveness.

02 Autoimmune Conditions

Studies examining treatments for various autoimmune and inflammatory conditions, with particular focus on psoriatic arthritis and lung-related complications.

  • Systemic Autoimmune Rheumatic Diseases
  • Psoriatic Arthritis
  • Bronchial Diseases

Research aims to evaluate new biological treatments and their long-term safety profiles.

03 Metabolic and Cardiovascular Research

Investigations into treatments for obesity and related cardiovascular conditions, including studies on innovative therapeutic approaches for metabolic disorders.

  • Obesity Management
  • Cardiovascular Safety
  • Transthyretin Amyloidosis

Clinical trials focusing on both treatment efficacy and cardiovascular safety outcomes.

Back to SpainAll countries
Clinical Trials Concierge

Prefer not to search? Our Concierge searches the trials for you.

Tell us about your condition – we search every trial in Europe and connect you with the right site.